A 64-year-old man with low-risk prostate cancer: Review of prostate cancer treatment

JAMA

Volumn 301, Issue 20, 2009, Pages 2141-2151

  Sanda, Martin G ^a,b   Kaplan, Irving D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ATORVASTATIN; DULOXETINE; LORAZEPAM; PROSTATE SPECIFIC ANTIGEN; SILDENAFIL;

ADULT; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CASE REPORT; DEPRESSION; EARLY DIAGNOSIS; ERECTILE DYSFUNCTION; EVENING DOSAGE; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; INCIDENTAL FINDING; MALE; OBSERVATIONAL METHOD; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SERODIAGNOSIS; TREATMENT PLANNING; ADENOCARCINOMA; BLOOD; CANCER STAGING; CLINICAL OBSERVATION; CLINICAL STUDY; DECISION SUPPORT SYSTEM; DIAGNOSIS; DISEASE COURSE; MIDDLE AGED; NEEDLE BIOPSY; PROSTATE TUMOR; RADIOTHERAPY; RISK ASSESSMENT; RISK FACTOR;

ADENOCARCINOMA; BIOPSY, NEEDLE; DECISION SUPPORT TECHNIQUES; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; RISK ASSESSMENT; RISK FACTORS;

EID: 66149123684     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.674     Document Type: Article

References (67)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96.
2. Collin SM, Martin RM, Metcalfe C, et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol. 2008;9(5):445-452.
3. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin. 2006;56(1):11-25. (Pubitemid 43228384)
4. Andriole GL, Crawford ED, Grubb RL 3rd, et al; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial [published correction in N Engl J Med. 2009;360(17):1797]. N Engl J Med. 2009;360(13):1310-1319.
5. Schröder FH, Hugosson J, Roobol MJ, et al; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-1328.
6. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998;280(11):975-980. (Pubitemid 28445095)
7. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA. 2004;291(22):2713-2719. (Pubitemid 38725420)
8. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433-439. (Pubitemid 41124175)
9. Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA. 1999;281(17):1598-1604. (Pubitemid 29211768)
10. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969-974. (Pubitemid 28445094)
11. Bill-Axelson A, Holmberg L, Ruutu M, et al; Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352(19):1977-1984.
12. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337(5):295-300. (Pubitemid 27318990)
13. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292(7):821-827. (Pubitemid 39079668)
14. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341(24):1781-1788.
15. Soloway MS, Pareek K, Sharifi R, et al; Lupron Depot Neoadjuvant Prostate Cancer Study Group. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol. 2002;167(1):112-116.
16. Wilt TJ. SPCG-4: a needed START to PIVOTal data to promote and protect evidence-based prostate cancer care. J Natl Cancer Inst. 2008;100(16):1123-1125.
17. Wallace K, Fleshner N, Jewett M, Basiuk J, Crook J. Impact of a multidisciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol. 2006;24(25):4158-4162. (Pubitemid 46622293)
18. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271(5):368-374. (Pubitemid 24037911)
19. Warlick C, Trock B, Landis P, Epstein J, Carter H. Delayed vs immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst. 2006;98(5):355-357. (Pubitemid 43338215)
20. Zietman AL, Thakral H, Wilson L, Schellhammer P. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. J Urol. 2001;166(5):1702-1706. (Pubitemid 32953390)
21. Carter CA, Donahue T, Sun L, et al. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol. 2003;21(21):4001-4008. (Pubitemid 46606215)
22. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol. 2006;24(1):46-50. (Pubitemid 43097357)
23. Meng MV, Elkin EP, Harlan SR, Mehta SS, Lubeck DP, Carroll PR. Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE. J Urol. 2003;170(6 pt 1):2279-2283. (Pubitemid 37413975)
24. Wong YN, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men [published correction appears in JAMA. 2007:297(1):42]. JAMA. 2006;296(22):2683-2693.
25. Thompson I, Thrasher JB, Aus G, et al; AUA Prostate Cancer Clinical Guideline Update Panel. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177(6):2106-2131.
26. Scherr D, Swindle PW, Scardino PT; National Comprehensive Cancer Network. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology. 2003;61(2)(suppl 1):14-24. (Pubitemid 36349538)
27. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250- 1261.
28. Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA. 2000;283(3):354-360. (Pubitemid 30051753)
29. Quinlan DM, Epstein JI, Carter BS, Walsh PC. Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol. 1991;145(5):998-1002.
30. Catalona WJ, Carvalhal GF, Mager DE, Smith DS. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol. 1999;162(2):433-438. (Pubitemid 29434355)
31. Rabbani F, Stapleton A, Kattan M, Wheeler T, Scardino P. Factors predicting recovery of erections after radical prostatectomy. J Urol. 2000;164(6):1929-1934.
32. Steineck G, Helgesen F, Adolfsson J, et al; Scandinavian Prostatic Cancer Group Study Number 4. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002;347(11):790-796.
33. Potosky A, Legler J, Albertsen P, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the prostate cancer outcomes study. J Natl Cancer Inst. 2000;92(19):1582-1592.
34. Guillonneau B, Vallancien G. Laparoscopic radical prostatectomy: the Montsouris technique. J Urol. 2000;163(6):1643-1649. (Pubitemid 30366705)
35. Menon M, Tewari A; Vattikuti Institute Prostatectomy Team. Robotic radical prostatectomy and the Vattikuti Urology Institute technique: an interim analysis of results and technical points. Urology. 2003;61(4)(suppl 1):15-20. (Pubitemid 36349125)
36. Hu J, Wang Q, Pashos C, Lipsitz S, Keating N. Utilization and outcomes of minimally invasive radical prostatectomy. J Clin Oncol. 2008;26(14):2278-2284.
37. Bagshaw M, Kaplan H, Sagerman R. Linear accelerator supervoltage radiotherapy, vii: carcinoma of the prostate. Radiology. 1965;85:121-129.
38. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial [published correction appears in JAMA. 2008;27;299(8):899-900]. JAMA. 2005;294(10):1233-1239.
39. Kuban D, Tucker S, Dong L, et al. Long-term results of the M. D. Anderson randomized dose escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):67-74. (Pubitemid 350251041)
40. Widmark A, Klepp O, Solberg A, et al; Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373(9660):301-308.
41. Pommie P, Chabaud S, Lagrange JL, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? preliminary results of GETUG-01. J Clin Oncol. 2007;25(34):5366-5373. (Pubitemid 350232211)
42. Lawton CA, DeSilvo M, RoachM III. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. 2008;69(3):646-655. (Pubitemid 47418390)
43. Litwin M, Hays R, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995;273(2):129-135.
44. Talcott J, Manola J, Clark J, et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol. 2003;21(21):3979-3986. (Pubitemid 46606212)
45. Madalinska J, Essink-Bot M, de Koning H, Kirkels W, van der Maas P, Schroder F. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol. 2001;19(6):1619-1628. (Pubitemid 32230861)
46. D'Amico A, Denham J, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25(17):2420-2425. (Pubitemid 46999213)
47. LeborgneF, Fowler J. Acute toxicity after hypofractionated conformal radiotherapy for localized prostate cancer: nonrandomized contemporary comparison with standard fractionation. Int J Radiat Oncol Biol Phys. 2006;72(3):780-786.
48. Kupelian PA, Willoughby TB, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic Experience. Int J Radiat Oncol Biol Phys. 2007;68(5):1424-1430. (Pubitemid 47176809)
49. Di Muzio N, Fiorino C, Cozzarini C, et al. Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer [published online December 2, 2008]. Int J Radiat Oncol Biol Phys. 2008. doi:10.1016/j.ijrobp.2008.08.038.
50. King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC Jr. Sterotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2009;73(4):1043-1048.
51. Blasko J, Mate T, Sylvester J, Grimm P, Cavanagh W. Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes. Semin Radiat Oncol. 2002;12:81-94. (Pubitemid 34094799)
52. Herstein A, Wallner K, Merrick G, et al. I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial Cancer J. 2005;11(5):385-389. (Pubitemid 41725729)
53. Lawton C, DeSilvio M, Lee W, et al. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (Radiation Therapy Oncology Group 98-05). Int J Radiat Oncol Biol Phys. 2007;67(1):39-47. (Pubitemid 44959487)
54. Lee W, Bae K, Lawton C, et al. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group Study 0019. Cancer. 2007;109(8):1506-1512. (Pubitemid 46595685)
55. Radiation Therapy Oncology Group. Interstitial brachytherapy with or without external beam radiotherapy in patients with intermediate risk prostate Cancer. ClinicalTrials.gov NCT00063882. http://clinicaltrials.gov/ct2/results? term=00063882. Accessed May 5, 2009.
56. Wallner K, Ellis W, Russell K, et al. Use of TRUS to predict pubic arch interference of prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1999;43(3):583-585. (Pubitemid 29107179)
57. Gelblum DY, Potters L, Ashley R, et al. Urinary morbidity following ultrasound guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys. 1999;45(1):39-67. (Pubitemid 29380075)
58. Zelefsky MJ, Reuter VE, Fuks Z, Scardino P, Shippy A. Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol. 2008;179(4):1368-1373, discussion 1373.
59. Crook JM, Malone S, Perry G, et al. Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: results from a Canadian randomized trial. Cancer. 2009;115(3):673-679.
60. Stone NN, Stock RG, White I, Unger P. Patterns of local failure following prostate brachytherapy. J Urol. 2007;177(5):1759-1764. (Pubitemid 46560659)
61. Fagerlin A, Rovner D, Stableford S, Jentoft C, Wei J, Holmes-Rovner M. Patient education materials about the treatment of early-stage prostate cancer: a critical review. Ann Intern Med. 2004;140(9):721-728. (Pubitemid 38568988)
62. Holmes-Rovner M, Stableford S, Fagerlin A, et al. Evidence-based patient choice: a prostate cancer decision aid in plain language. BMC Med Inform Decis Mak. 2005;5:16. (Pubitemid 41096329)
63. Small E, Frohlich M, Bok R, et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol. 2000;18(21):3595-3603.
64. Clement J, Bubley G. Prostasol and venous thromboembolism. Urology. 2008;72(3):664-666.
65. Platz E, Leitzmann M, Visvanathan K, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst. 2006;98(24):1819-1825. (Pubitemid 46017933)
66. Begg C, Riedel E, Bach P, et al. Variations in morbidity after radical prostatectomy. N Engl J Med. 2002;346(15):1138-1144. (Pubitemid 34984605)
67. Wu A, Cooperberg M, Sadetsky N, Carroll P. Health related quality of life in patients treated with multimodal therapy for prostate cancer. J Urol. 2008;180(6):2415-2422.